Magnetocardiography for Cardiac Amyloidosis
A Prospective Study of Magnetocardiography for Disease Detection and Monitoring Treatment Outcomes in Amyloidosis
This project tests whether magnetocardiography (MCG) can help diagnose and monitor heart involvement in adults with amyloidosis compared with ECG and other standard tests.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT07218705 on ClinicalTrials.gov |
What this trial studies
This observational study uses the SandboxAQ CardiAQ magnetocardiography device to record cardiac magnetic signals in adults with amyloidosis. Participants will undergo MCG scans alongside standard clinical tests such as 12‑lead ECG, and clinical data will be collected to compare diagnostic and monitoring performance. The protocol is non-interventional and conducted at a single site, with enrollment limited to adults who can lie supine and have no active thoracic metal implants or atrial fibrillation. Investigators will analyze correlations between MCG measurements, ECG findings, and clinical indicators of disease progression.
Who should consider this trial
Good fit: Adults (age ≥18) with diagnosed or suspected amyloidosis who can consent, lie still for an MCG scan, and do not have thoracic metal implants or active atrial fibrillation are the ideal candidates.
Not a fit: Patients with implanted cardiac devices, active atrial fibrillation, those who cannot lie supine or remain still, pregnant or breastfeeding individuals, or those unable to travel to Mayo Clinic Rochester are unlikely to benefit from participating.
Why it matters
Potential benefit: If successful, MCG could offer a noninvasive, more sensitive way to detect and track cardiac amyloidosis earlier than ECG, potentially guiding care and reducing need for invasive tests.
How similar studies have performed: MCG has shown promise in small studies for detecting cardiac electrical abnormalities, but its application specifically to cardiac amyloidosis is relatively novel with limited prior data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria 1. Age ≥ 18 years on the date of consent 2. Ability for participant to comply with study requirements 3. Written informed consent Exclusion Criteria 1. Pregnant or breastfeeding 2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG 3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator). 4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan 5. Inability to lie down in a supine/inclined position and stay still on the examination bed 6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
Where this trial is running
Rochester, Minnesota
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Mohamad Alkhouli, M.D., M.B.A. — Mayo Clinic
- Study coordinator: Andy Dang
- Email: dang.phong@mayo.edu
- Phone: 507-255-7752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.